MENU

Eureka projects

The scope of this project is to complete the r&d required for obtaining the market authorization of a new recombinant vaccine against canine leishmaniasis, which has been shown protective in experimental trials in dogs with better performance than that of gold-standards.
Project ID: 
11694

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.